ProQR Therapeutics (NASDAQ:PRQR) Stock Passes Above Fifty Day Moving Average - Time to Sell?

Shares of ProQR Therapeutics (NASDAQ:PRQR - Get Free Report) passed above its fifty day moving average during trading on Tuesday . The stock has a fifty day moving average of $2.48 and traded as high as $2.63. ProQR Therapeutics shares last traded at $2.58, with a volume of 228,832 shares trading hands.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on the company. Raymond James raised ProQR Therapeutics from an "outperform" rating to a "strong-buy" rating and boosted their price target for the company from $6.00 to $14.00 in a research note on Tuesday, October 29th. Oppenheimer assumed coverage on ProQR Therapeutics in a research note on Friday, January 10th. They issued an "outperform" rating and a $15.00 price target for the company. Chardan Capital reaffirmed a "buy" rating and issued a $4.00 price target on shares of ProQR Therapeutics in a research note on Thursday, December 12th. JMP Securities reissued a "market outperform" rating and set a $8.00 target price on shares of ProQR Therapeutics in a research note on Thursday, December 12th. Finally, StockNews.com downgraded ProQR Therapeutics from a "hold" rating to a "sell" rating in a research note on Thursday, November 28th. One investment analyst has rated the stock with a sell rating, five have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $8.83.

ProQR Therapeutics Stock Down 0.8 %

The stock has a market cap of $209.10 million, a price-to-earnings ratio of -8.00 and a beta of 0.25. The company has a 50 day simple moving average of $2.44 and a 200 day simple moving average of $2.61.

Institutional Trading of ProQR Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the company. BNP Paribas Financial Markets grew its holdings in shares of ProQR Therapeutics by 14.2% during the third quarter. BNP Paribas Financial Markets now owns 58,801 shares of the biopharmaceutical company's stock worth $107,000 after purchasing an additional 7,300 shares during the last quarter. OneDigital Investment Advisors LLC grew its holdings in shares of ProQR Therapeutics by 37.0% during the third quarter. OneDigital Investment Advisors LLC now owns 57,550 shares of the biopharmaceutical company's stock worth $105,000 after purchasing an additional 15,550 shares during the last quarter. Ballentine Partners LLC bought a new stake in shares of ProQR Therapeutics during the fourth quarter worth about $61,000. Privium Fund Management B.V. grew its holdings in shares of ProQR Therapeutics by 0.9% during the third quarter. Privium Fund Management B.V. now owns 5,632,388 shares of the biopharmaceutical company's stock worth $10,251,000 after purchasing an additional 51,663 shares during the last quarter. Finally, Affinity Asset Advisors LLC bought a new stake in shares of ProQR Therapeutics during the fourth quarter worth about $7,486,000. 32.65% of the stock is currently owned by institutional investors.

ProQR Therapeutics Company Profile

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).